results of 2024 ASM

Page 1 of 1
2 August 2024
Results of 2024 Annual Shareholder Meeting

At AFT Pharmaceuticals Limited’s (NZX: AFT / ASX: AFP) annual shareholder meeting held at the
Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand today, shareholders were
asked to vote on four resolutions, all of which were supported by the Board.

As required by NZX Listing Rule 6.1, all voting was conducted by a poll.

The resolutions passed by shareholders were:

1. That the directors are authorised to fix the fees and expenses of Deloitte as auditor for
the 2025 financial year.

2.
That David Flacks be re-elected as a director of AFT Pharmaceuticals Limited.

3. That Dr Ted Witek be re-elected as a director of AFT Pharmaceuticals Limited.

4. That Andrew Lane be elected as a director of AFT Pharmaceuticals Limited.


Detail of the total number of votes cast in person or by a proxy holder are:

Resolution For Against Abstain

1. That the directors are authorised to fix the
fees and expenses of Deloitte as auditor
for the 2025 financial year.

87,075,769
99.96%

38,538
0.04%


28,681



2. That David Flacks be re-elected as a
director of AFT Pharmaceuticals Limited.

87,111,702
99.99%
6,480
0.01%
24,806


3. That Dr Ted Witek be re-elected as a
director of AFT Pharmaceuticals Limited.

87,114,698
99.99%
6,093
0.01%
22,197


4. That Andrew Lane be elected as a
director of AFT Pharmaceuticals Limited.

87,111,025
99.99%
9,946
0.01%
22,017


Authority for this announcement
Name of person authorised to make this
announcement
Malcolm Tubby, Chief Financial Officer
Contact person for this announcement Malcolm Tubby
Contact phone number +64 9 488 0232
Contact email address Investor.relations@aftpharm.com
Date of release through MAP 2 August 2024